Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4
Open Access
- 13 January 2013
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 32 (6) , 745-754
Abstract
IL-28B polymorphisms are predictors of response to therapy in adults infected with hepatitis C. We do not know whether they are markers of response to therapy in children and adolescents. The aim of this study was to determine whether single-nucleotide polymorphisms (SNPs) in the IL-28B gene could influence the probability of response to therapy compared with other known baseline prognostic factors and correlate with clinical findings in pediatric patients infected with hepatitis C virus (HCV) genotypes 1 or 4. We determined three SNPs of IL-28B (rs12979860, rs12980275, and rs8099917) in 82 patients with chronic HCV infection treated with pegylated interferon alpha and ribavirin (peg-IFNα/RBV). Treatment response and clinical data were analyzed. Overall, sustained virological response (SVR) was achieved by 45 % of patients infected with difficult-to-treat HCV genotypes 1 and 4. Except for IL-28B polymorphisms, there was no association of SVR with any other clinical data. IL-28B rs12979860 CC [odds ratio (OR), 6.81; p = 0.001] and rs8099917 TT (OR, 3.14; p = 0.013) genotypes were associated with higher SVR rates. IL-28B rs12980275 was not significantly associated with SVR (p = 0.058). Only the distribution between CC and CT–TT genotypes of rs12979860 significantly differentiated patients achieving early virological response (EVR) (OR, 10.0; p = 0.011). Children with the rs12979860 CC genotype had significantly higher baseline viral load compared with CT–TT patients (p = 0.010). In children and adolescents chronically infected with HCV genotypes 1 and 4, IL-28B rs12979860 and rs8099917 polymorphisms were the only predictors of response to peg-IFN/RBV.Keywords
This publication has 27 references indexed in Scilit:
- 1329 INFLUENCE OF IL28B GENE POLYMORPHISMS ON SUSTAINED RESPONSE TO PEGINTERFERON PLUS RIBAVIRIN IN CHILDREN WITH CHRONIC HEPATITIS CJournal of Hepatology, 2011
- The Combination of Ribavirin and Peginterferon Is Superior to Peginterferon and Placebo for Children and Adolescents With Chronic Hepatitis CGastroenterology, 2011
- Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirinLiver International, 2010
- Replicated Association Between an IL28B Gene Variant and a Sustained Response to Pegylated Interferon and RibavirinGastroenterology, 2010
- Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescentsJournal of Hepatology, 2010
- Genetic variation in IL28B and spontaneous clearance of hepatitis C virusNature, 2009
- Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis CJournal of Gastroenterology, 2009
- Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C InfectionNew England Journal of Medicine, 2009
- Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factorsHepatology, 2008
- Efficacy and Safety of Peginterferon-α2b and Ribavirin Combination Therapy in Children With Chronic Hepatitis C InfectionThe Pediatric Infectious Disease Journal, 2008